The Good Place (2016-2020)

Study discovers that mitochondria transmit signals in the immune and nervous systems

The new study has revealed that mitochondria play a crucial role in the regulation of the NF-κB signaling pathway.

Mitochondria are primarily known as the powerhouse of the cell. However, these cellular organelles are required not only for providing energy: Professor Konstanze Winklhofer and her group at the Faculty of Medicine at Ruhr University Bochum, Germany, recently discovered that mitochondria play an important role in signal transduction in innate immune pathways.

They regulate a signaling pathway that helps to eliminate pathogens, but can cause damage through inflammation upon overactivation. The research team published their findings in the EMBO Journal.

Continue Reading.

fruitie punches

your bulldog isn’t being quirky it’s actively trying not to die every 10 seconds

biology is like the self discovery journey of a bunch of cells

candida and lactobacillus image under microscope / routine laboratory diaries

The public paid for "Moderna's" vaccine, and now we're going to pay again (and again and again)

Moderna is quadrupling the cost of covid vaccines, from $26/dose to $110–130. Moderna CEO Stephane Bancel calls the price hike “consistent with the value” of the mRNA vaccines. Moderna’s manufacturing costs are $2.85/dose, for a 4,460% markup on every dose:

https://arstechnica.com/science/2023/01/moderna-may-match-pfizers-400-price-hike-on-covid-vaccines-report-says/

If you’d like an essay-formatted version of this thread to read or share, here’s a link to it on pluralistic.net, my surveillance-free, ad-free, tracker-free blog:

https://pluralistic.net/2023/01/24/nationalize-moderna/#herd-immunity

Keep reading

Remember, folks, never pay to access a scientific article. Use a site like Sci-Hub, or failing that, e-mail the authors and request the data you need. Elsevier and their ilk are hoarders and thieves of knowledge, and they don’t deserve one cent more. Poach and pirate away; it is entirely justified.

Good bacteria may eliminate bad bacteria better than antibiotics

Experimental technology is like a microscopic poison arrow shot from a good bacterium to eliminate a bad bacterium under specific conditions.

The bacteria wars are coming. Researchers at Tel Aviv University have pitted “good” bacteria against “bad” bacteria and the good guys, it appears, are winning.

If the system can be scaled, this new approach could potentially replace antibiotics, which are increasingly struggling against antibiotic-resistant “superbugs.” For the TAU study, the researchers used a toxin injection system known as a “Type 6 Secretion System.” It’s usually deployed by pathogenic (“bad”) bacteria. They introduced the system into a “friendly” bacterium, Vibrio natriegens, which is not harmful to humans. The researchers described their technology as similar to a microscopic poison arrow shot from a good bacterium to eliminate a bad bacterium under specific conditions. “The system that we built allows us to engineer ‘good’ bacteria that can recognize pathogenic bacteria, attack them with toxins, and neutralize them,” explains Dr. Dor Salomon, who co-led the study. “We know how to change and control every component in the system and create a bacterium that neutralizes different strains of bacteria. This is proof of feasibility, showing that we have the knowledge and ability to create bacteria that take advantage of this killing system and may serve as antibiotic treatments. ”The current bacteria prototype is best suited for bugs that occur naturally in saltwater. This is a growing concern, as fish and seafood constitute a major food source in many regions of the world. “Their productivity is severely impaired as a result of bacteria-borne diseases,” Solomon notes, “and since we want to avoid pouring antibiotics into aquaculture farms, a biological solution such as the one we have developed is an effective alternative.” The system will eventually be adapted to treat pathogenic bacteria in humans, farm animals and plants. Tel Aviv University has filed a patent application through Ramot, the university’s technology-transfer company. In addition to Solomon, Dr. Biswanath Jana and Kinga Kappel of the department of clinical microbiology and immunology at TAU’s Sackler Faculty of Medicine participated in the research. The results were published this month in the scientific journal EMBO Reports.